Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Antibiotics for induction and maintenance of remission in Crohn's disease

Esta versión no es la más reciente

Información

DOI:
https://doi.org/10.1002/14651858.CD012730Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 21 julio 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Salud digestiva

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Cassandra M Townsend

    Department of Medicine, University of Western Ontario, London, Canada

  • Claire E Parker

    Robarts Clinical Trials, London, Canada

  • John K MacDonald

    Department of Medicine, University of Western Ontario, London, Canada

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

  • Vipul Jairath

    Department of Medicine, University of Western Ontario, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

  • Brian G Feagan

    Department of Medicine, University of Western Ontario, London, Canada

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

  • Reena Khanna

    Correspondencia a: Department of Medicine, University of Western Ontario, London, Canada

    [email protected]

Declarations of interest

Cassandra M Townsend: None known

Vipul Jairath: Dr. Jairath has received scientific advisory board fees from Abbvie, Sandoz, Ferring, Janssen, Takeda; speakers fees from Takeda, Janssen, Shire and Ferring; travel support for conference attendance from Vifor pharmaceuticals. All of these financial activities are outside of the submitted work.

Claire E Parker: None known

Brian G Feagan: Dr Feagan has received fees from Abbott/AbbVie, Amgen, Astra Zeneca, Avaxia Biologics Inc., Bristol‐Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring, JnJ/Janssen, Merck, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, Tillotts Pharma AG, UCB Pharma for Board membership; fees fromAbbott/AbbVie, Actogenix, Albireo Pharma, Amgen, Astra Zeneca, Avaxia Biologics Inc., Axcan, Baxter Healthcare Corp., Boehringer‐Ingelheim, Bristol‐Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Merck, Millennium, Nektar, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, Tillotts, UCB Pharma, Vertex Pharma, Warner‐Chilcott, Wyeth, Zealand, and Zyngenia for consultancy; and Payment for lectures from Abbott/AbbVie, JnJ/Janssen, Takeda, Warner‐Chilcott, UCB Pharma. All of these financial activities are outside of the submitted work.

John K MacDonald: None known

Reena Khanna: Dr. Khanna has received consulting fees from AbbVie, Janssen, Pfizer, Shire, Takeda. All of these financial activities are outside of the submitted work.

Acknowledgements

Partial funding for the Cochrane IBD Group (April 1, 2016 ‐ March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC).

Version history

Published

Title

Stage

Authors

Version

2019 Feb 07

Antibiotics for induction and maintenance of remission in Crohn's disease

Review

Cassandra M Townsend, Claire E Parker, John K MacDonald, Tran M Nguyen, Vipul Jairath, Brian G Feagan, Reena Khanna

https://doi.org/10.1002/14651858.CD012730.pub2

2017 Jul 21

Antibiotics for induction and maintenance of remission in Crohn's disease

Protocol

Cassandra M Townsend, Claire E Parker, John K MacDonald, Vipul Jairath, Brian G Feagan, Reena Khanna

https://doi.org/10.1002/14651858.CD012730

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.